Texas Banned Hemp THC Without Passing a Bill: What Patients Have Left

Texas did not pass a hemp THC ban. It got one anyway. On May 1, 2026 the Supreme Court of Texas decided Texas Department of State Health Services v. Sky Marketing Corp., No. 23-0887, holding that the DSHS commissioner acted within her lawful authority when she modified the state controlled substances schedules to classify manufactured delta-8 THC as Schedule I, and reversing the temporary injunction that had blocked that classification since 2021.

DSHS then reinstated the 2021 clarifications to the schedule definitions of tetrahydrocannabinols and marihuana extract, effective July 31, 2026. Products labeled as containing delta-8, or found to contain more than trace naturally occurring amounts, may be detained and referred to law enforcement.

For five years Texas patients bought hemp-derived THC from ordinary retail: vape shops, convenience stores, wellness storefronts. Many of them were treating pain, sleep, anxiety, or nausea, and many had never enrolled in a medical program because they did not need to. That channel closed on July 31.

A closed channel does not close demand. It closes visibility. The patients who used those products are still symptomatic, and the ones who do not know that Texas has a functioning prescribing pathway will find a substitute on their own. The clinically useful contribution here is telling them what the pathway is and who qualifies.

June 22, 2025: Governor Abbott vetoed Senate Bill 3, the legislature’s attempt at a broad hemp THC ban. His veto statement argued the bill would face the same constitutional challenge that defeated Arkansas’s comparable law and would be, in his words, dead on arrival in court. He called a special session to write a regulatory framework instead.

September 10, 2025: Abbott issued Executive Order GA-56, directing DSHS and the Texas Alcoholic Beverage Commission to ban sales of hemp products to minors and require government-issued identification at the point of sale, directing DSHS to strengthen testing, labeling, licensing, and recordkeeping rules, and directing DSHS, TABC, and the Department of Public Safety to coordinate enforcement. DSHS adopted emergency rules on October 2, 2025 barring sales to anyone under 21.

May 1, 2026: the Supreme Court of Texas decided DSHS v. Sky Marketing Corp. The court found the vendors had standing and the case was ripe, then held that the commissioner properly exercised her discretion under the Texas Controlled Substances Act, that the scheduling did not conflict with the 2019 Texas farm bill, and that the Administrative Procedure Act claim failed. The temporary injunction was reversed.

July 31, 2026: the reinstated schedule definitions took effect. The ban Texans are living under is an agency schedule upheld by a court, not a statute.

DSHS states that delta-8 tetrahydrocannabinol is a controlled substance and that only naturally occurring trace amounts present in the hemp plant from which a consumable hemp product was manufactured are permissible. Products labeled to contain delta-8, or testing above trace amounts, may be detained and referred to law enforcement. The reinstated definitions reach tetrahydrocannabinols and marihuana extract broadly, which is why the practical effect has extended past delta-8 to the wider family of converted and high-potency hemp THC products sold in Texas retail.

What remains permitted under state law is narrow and specific: consumable hemp products containing delta-9 tetrahydrocannabinol at not more than 0.3 percent on a dry weight basis. That is the statutory hemp threshold, and it is a concentration limit rather than a milligram limit, which is a distinction patients rarely appreciate.

Smokable hemp sits in its own tangle. DSHS notes that the Texas Supreme Court upheld the statute prohibiting the processing or manufacturing of a consumable hemp product for smoking, while a lower court injunction has allowed distribution and retail sale of such products to continue. A patient should not take that as a green light. It is unresolved litigation, not a permission.

In July 2026 Senator Charles Perry, who authored the vetoed Senate Bill 3, told reporters after an interim Senate hearing that he would file another THC ban in the next session. That is a stated intention, and it is worth knowing about, but it is not a pending bill and it should not be described as one.

The Texas Legislature meets in regular session only in odd-numbered years. The 90th Legislature convenes in January 2027. Until then there is no vehicle to consider, no committee referral, no hearing schedule, and no bill number. Anyone reading that Texas is about to ban THC is reading about a plan for next year, not about the rule that closed their local shop this summer.

That gap matters practically. A patient who thinks the ban is still a proposal may keep looking for the product, or may assume a store selling it is operating legally. The schedule took effect July 31, 2026 regardless of what the legislature does in 2027.

Two challenges are running. In state court, the Texas Hemp Business Council and industry plaintiffs have contested DSHS rulemaking. In federal court, hemp retailers and a distributor sued DSHS, the attorney general, and Galveston County officials in the Southern District of Texas, arguing that the state’s treatment of hemp-derived THC conflicts with federal law and the Constitution.

In August 2026, United States District Judge Jeffrey V. Brown denied the plaintiffs’ emergency motion for a temporary restraining order in the Galveston case, leaving the schedule in force. A restraining order is emergency relief held to a demanding standard, and its denial is not a ruling on the merits. The request for a preliminary injunction remains pending with fuller briefing to come, and no ruling on it had issued as this page was written.

For a patient, the practical reading is simple. Litigation outcomes are not a plan. Until a court enjoins the schedule, the products are scheduled, and possessing or buying them carries the risk that comes with a Schedule I listing in Texas.

While the hemp channel closed, the prescribing channel widened. House Bill 46 of the 89th Legislature took effect September 1, 2025 and substantially rebuilt the Texas Compassionate Use Program. It redefined low-THC cannabis as containing not more than 10 milligrams of tetrahydrocannabinols per dosage unit, replacing the old one percent by weight standard, which for the first time gives Texas prescribers a milligram to work with.

The qualifying condition list in Section 169.003 of the Occupations Code now includes epilepsy, a seizure disorder, multiple sclerosis, spasticity, amyotrophic lateral sclerosis, autism, cancer, an incurable neurodegenerative disease, post-traumatic stress disorder, a condition that causes chronic pain, traumatic brain injury, Crohn’s disease or other inflammatory bowel disease, and terminal illness or a condition for which the patient is receiving hospice or palliative care. Chronic pain is defined in the statute as pain not relieved by acute, post-surgical, post-procedure, or persistent non-chronic treatment, associated with a chronic pathological process producing continuous or intermittent severe pain for more than 90 days, and for which tetrahydrocannabinol is a viable treatment.

House Bill 46 also added Section 169.006, permitting a physician to prescribe pulmonary inhalation of an aerosol or vapor when there is a medical necessity for that route, with the prescription specifying the amount of tetrahydrocannabinols per dosage unit. Smoking remains outside the definition of medical use. Dispensing is capped at one gram of total tetrahydrocannabinols per package or per inhalation device.

Access is expanding on the supply side as well. Texas had three operating dispensing organizations. Under House Bill 46 the Department of Public Safety ran a two-phase selection for twelve additional licenses, announcing nine selections in December 2025 and three more on April 1, 2026. DPS has cautioned that selection does not guarantee a final license, and the statute requires a license holder to begin dispensing within 24 months. Satellite locations are now permitted within public health regions, and political subdivisions may not prohibit low-THC cannabis.

Texas is ahead of a federal shift rather than out of step with it. Section 781 of Public Law 119-37, signed November 12, 2025, rewrites the federal hemp definition to exclude hemp-derived cannabinoid products containing cannabinoids a Cannabis sativa L. plant cannot naturally produce, cannabinoids synthesized or manufactured outside the plant, and any final product with more than 0.4 milligrams of combined total tetrahydrocannabinols per container.

On September 2, 2026 the President signed H.R. 6500, whose Section 2019 provides that until December 11, 2026 those amendments apply only to cannabinoids a plant cannot naturally produce. After that date the full definition applies, including the 0.4 milligram per container cap. Our explainer on the DEA drug code for HHC covers that sequence in detail.

The consequence for a Texas patient shopping in a neighboring state is worth naming. The products that remain available across a state line are on a federal clock of their own, and the container limit that arrives in December is far below what any commercial hemp THC product contains. Stocking up is not a strategy.

Every operative fact on this page comes from a primary source: the Supreme Court of Texas opinion in No. 23-0887, the DSHS Consumable Hemp Program notices, the enrolled text of House Bill 46 of the 89th Legislature, Executive Order GA-56 as issued by the Governor’s office, and the enrolled federal text of Public Law 119-37 and H.R. 6500. Dates and holdings are quoted from those records rather than from coverage of them.

The weaker ground is enforcement practice. What a schedule says and what county prosecutors and local police actually do with it are different questions, and they vary considerably across Texas. A patient should treat the schedule as the rule and local practice as unknowable from a distance.

The safety case that drove this outcome deserves scrutiny alongside the outcome itself. The July 2026 Senate interim hearing that generated the renewed ban push took no testimony from the hemp industry, and attorneys following the proceeding described it as thin on medical and scientific expertise. Child exposure and poison center concerns about hemp THC products are real and documented elsewhere. A one-sided hearing can surface a genuine harm while leaving the question of the best remedy underexamined.

Skepticism runs the other direction too. The hemp industry’s argument that these products were adequately regulated does not survive contact with the testing literature, which has repeatedly found label deviations and undeclared cannabinoids in retail hemp THC products. Neither side of this fight has clean hands on the evidence.

None of this establishes that hemp-derived THC products are more dangerous than the low-THC cannabis Texas permits by prescription. The distinction the state has drawn is regulatory and jurisdictional, resting on where a cannabinoid came from and how it was made, not on a head-to-head safety comparison.

It also does not show that the ban will reduce harm. Prohibiting a retail channel changes where people obtain a product and how much is known about what they are taking. Whether that lowers or raises net risk in Texas is an empirical question that nobody has answered, and the schedule taking effect is not the answer.

Texas is the largest test yet of a pattern appearing in several states: a hemp THC market that grew under a federal definition, a state that decides the definition was never meant to permit it, and an enforcement mechanism that arrives through agency action and litigation rather than through a vote. The politics get the coverage. The scheduling notice does the work.

The more interesting development is that Texas closed one door and opened another in the same eighteen months. A state with no adult-use market now has a prescribing program with a milligram-based dosage standard, a chronic pain qualifying condition, a permitted inhalation route under medical necessity, and a licensing expansion designed around public health regions. That is a more clinically coherent system than the one it replaced.

The part I would want a Texas patient to hear is that the thing they lost and the thing they can get are not the same product, and the replacement is in some ways the better one. A prescribed preparation with a stated milligram per dosage unit, dispensed by a licensed organization, is easier to titrate and easier to reason about than a gas station gummy with an unverified label.

The barrier is not qualification for most of the people I would expect to be affected. Chronic pain is on the list, with a statutory definition that a great many patients meet. Post-traumatic stress disorder is on the list. Cancer is on the list. The barrier is that nobody told them the list changed.

What worries me about the next few months is substitution in the dark. When a familiar product disappears, people do not stop. They buy something less familiar from a less accountable source, at a dose they have no way to estimate. That is the period where the emergency department visits come from, and it is entirely preventable with a five minute conversation.

The Texas delta-8 ban is in force. It arrived through the Supreme Court of Texas on May 1, 2026 and through the state controlled substances schedule on July 31, 2026, not through a bill, and the legislature that might pass one does not convene until January 2027. Consumable hemp with delta-9 THC at or below 0.3 percent by dry weight remains permitted. Patients with epilepsy, chronic pain, post-traumatic stress disorder, cancer, multiple sclerosis, and the other conditions listed in Section 169.003 should be evaluated for the Texas Compassionate Use Program rather than left to find a substitute alone.

Separate three things that keep getting reported as one. There is a ban already in effect, delivered by an agency and a court. There is litigation that has not changed it. And there is a bill a senator says he will file in a session that has not started. Only the first one governs what is on a Texas shelf today.